2025-523706-32-00
Not yet recruiting
Phase 1
To evaluate the pharmacokinetics and safety of nolasiban
ReproNovo ApS1 site in 1 country28 target enrollmentStarted: January 9, 2026Last updated:
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- ReproNovo ApS
- Enrollment
- 28
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
ReproNovo Aps (contact)
Scientific
ReproNovo ApS
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.2025-523587-20-00Gruenenthal GmbH24
Completed
Phase 1
Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anapen® device and to compare the adrenaline comparative bioavailability with Anapen®500 commercial form in healthy normal weight male subjects2023-508117-16-00Bioprojet Pharma20
Not yet recruiting
Phase 1
A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants2024-516261-36-00Cinclus Pharma Holding AB (publ)113
Recruiting
Phase 1
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma2023-504304-29-00F. Hoffmann-La Roche AG30
Completed
Phase 1
Safety, tolerability and pharmacokinetics of intra‐articular (IA) single ascending dose of 4P‐004 in patient with Kellgren and Lawrence grade 2 to 4 osteoarthritic (OA) knee2022-500271-31-004moving Biotech32